Imatinib mesylate inhibits AKT/mTOR signaling pathway in osteosarcoma cells and activates ERK1/2 phosphorylation: PDGFRα, a key target of osteosarcoma cells.

<p>Human, mouse and rat osteosarcoma were treated with various doses of imatinib mesylate to analyse the effects of the drug on intra-cellular signaling pathways. (<b>A</b>) Imatinib mesylate inhibits mTOR and Akt phosphorylation in human HOS and mouse MOS-J cells. RAD001 named everolimus (RAD), a mTOR inhibitor was used as a positive control. (<b>B</b>) Human Phospho-receptor tyrosine kinase array Kit was used to identify the molecular targets of imatinib mesylate. (C) Expression of PDGFRα and PDGFRβ analyzed in human, mouse and rat osteosarcoma cells by semi-quantitative RT-PCR.